D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
D-Cycloserine, known from tuberculosis therapy, has been widely introduced to neuropsychiatric studies, since its central active mechanism as a partial NMDA-agonist has been found. In this review, we evaluate its therapeutic potential in neuropsychological disorders and discuss its pitfalls in terms of dosing and application frequency as well as its safety in low-dose therapy. Therefore, we identified 91 clinical trials by performing a Medline search. We demonstrate in part preliminary but increasing evidence that D-cycloserine may be effective in various psychiatric diseases, including schizophrenia, anxiety disorders, addiction, eating disorders, major depression, and autism as well as in neurological diseases, including dementia, Alzheimer's disease, and spinocerebellar degeneration. D-Cycloserine in low-dose therapy is safe, but there is still a need for new drugs with higher specificity to the different N-methyl-D-aspartate-receptor subunits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“At low doses (<100 mg/day), DCS acts as a functional NMDA receptor antagonist, whereas relatively higher doses (>750 mg/day) accelerate glycine site NMDA receptor potentiation and produce DCS’s antidepressant and anxiolytic effects [168].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Applying extinction research and theory to cue‐exposure addiction treatments
Conklin, C. A., & Tiffany, S. T. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00014.x · Cited by 701
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 3×
“A huge meta-analysis (Norberg et al., 2008) of data from human and animal studies showed a significant, though moderate, positive effect of DCS on exposure therapy/ fear extinction.”
BackgroundInfluentialEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 1×
“The mechanism of action of DCS might change or even reverse under conditions with great stress and might be due to different surrounding neurotransmitter concentrations (Hood et al., 1989; Watson et al., 1990; Sheinin et al., 2001; Davis et al., 2006).”
BackgroundGoff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Glycine binding primes NMDA receptor internalization
Nong, Y., Huang, Y.-Q., Ju, W., Kalia, L. V., Ahmadian, G., Wang, Y. T., & Salter, M. W. (2003) · Nature · doi:10.1038/nature01497 · Cited by 429
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390 · cited 1×
“For more information on DCS as an augmentation strategy in CBT for anxiety disorders, see 2 detailed recent reviews (Hofmann et al., 2015; Singewald et al., 2015).”
BackgroundEffects of D-cycloserine on extinction of conditioned freezing.
Ledgerwood, L., Richardson, R., & Cranney, J. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.2.341 · Cited by 388
Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine
Nitsche, M. A., Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300517 · Cited by 385
Self-citationHess, G., Aizenman, C. D., & Donoghue, J. P. (1996) · Journal of Neurophysiology · doi:10.1152/jn.1996.75.5.1765 · Cited by 383
d-Cycloserine: A ligand for the coupled glycine receptor has partial agonist characteristics
Hood, W. F., Compton, R. P., & Monahan, J. B. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90379-0 · Cited by 308
Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209
Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors
Mota, S. I., Ferreira, I. L., & Rego, A. C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.013 · Cited by 206
A Pilot Study of d-Cycloserine in Subjects With Autistic Disorder
Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2115 · Cited by 199
Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190 · cited 2×
“With repeated applications, a reduction in efficacy has been shown in chronic administration of DCS in animals (Quartermain et al., 1994).”
BackgroundCarlsson, M. L. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050076 · Cited by 186
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Goff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 1×
“A further study with a dose of up to 1000 mg/d, however, then showed an improvement in depression symptoms (Heresco-Levy et al., 2013), indicating an antagonistic mechanism in doses starting at 500 mg/d in humans.”
BackgroundWatson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172
Limited impact of homeostatic plasticity on motor learning in humans
Kuo, M.-F., Unger, M., Liebetanz, D., Lang, N., Tergau, F., Paulus, W., & Nitsche, M. A. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.023 · Cited by 172
Self-citationHeresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167
Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats
Parnas, A. S., Weber, M. F., & Richardson, R. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.01.001 · Cited by 157
d-Cycloserine enhances implicit memory in Alzheimer patients
Schwartz, B. L., Hashtroudi, S., Herting, R. L., Schwartz, P., & Deutsch, S. I. (1996) · Neurology · doi:10.1212/wnl.46.2.420 · Cited by 149
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144 · cited 2×
“, 2003), according to which a single dose of DCS, but not repeated doses, may improve cognition in humans (Goff et al., 2008).”
BackgroundSubunit specificity and mechanism of action of NMDA partial agonist d-cycloserine
Sheinin, A., Shavit, S., & Benveniste, M. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00073-9 · Cited by 139
Improved Cognition in Alzheimer’s Disease With Short-Term D-Cycloserine Treatment
Tsai, G. E., Falk, W. E., Gunther, J., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.467 · Cited by 128
Hofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121 · cited 1×
“This is in line with the results of a recent multi-site study on CBT and DCS in social anxiety disorder (Hofmann et al., 2013).”
ResultNMDA receptors and fear extinction: implications for cognitive behavioral therapy
Davis, M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/mdavis · Cited by 116
GOFF, D. C., Herz, L. R., Posever, T. A., Shih, V. E., Tsai, G. E., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2032-2 · Cited by 116
Karavanova, I. D., Vasudevan, K., Cheng, J., & Buonanno, A. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.12.001 · Cited by 106
Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
Dravid, S. M., Burger, P. B., Prakash, A., Geballe, M. T., Yadav, R., Le, P., Vellano, K., Snyder, J. P., & Traynelis, S. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5390-09.2010 · Cited by 105
Effects of -cycloserine on negative symptoms in schizophrenia
Duncan, E., Szilagyi, S., Schwartz, M. P., Bugarski‐Kirola, D., Kunzova, A., Negi, S., Stephanides, M., Efferen, T. R., Angrist, B., Peselow, E. D., et al. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.013 · Cited by 94
van Berckel, B. N. M., Evenblij, C. N., van Loon, B. J., Maas, M. F., van der Geld, M. A. M., Wynne, H. J. A., van Ree, J. M., & Kahn, R. S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00014-7 · Cited by 93
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“A first study with 250 mg/d DCS as add-on therapy to various stable psychotropic medications failed to show positive results (Heresco-Levy et al., 2006).”
BackgroundSanta Ana, E. J., Rounsaville, B. J., Frankforter, T. L., Nich, C., Babuscio, T., Poling, J., Gonsai, K., Hill, K. P., & Carroll, K. M. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.023 · Cited by 88
NR1 and NR2 Subunit Contributions to N-Methyl-d-aspartate Receptor Channel Blocker Pharmacology
Monaghan, D. T., & Larsen, H. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36478-x · Cited by 87
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Silipo, G., & Shimoni, J. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798001242 · Cited by 85
Matsuoka, N., & Aigner, T. G. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20677-2 · Cited by 82
d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update
Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0532-2 · Cited by 80
Urbano, M., Okwara, L., Manser, P., Hartmann, K., Herndon, A., & Deutsch, S. I. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000033 · Cited by 76
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.029 · Cited by 73 · cited 10×
“Further promising results have been found, especially for the combination of DCS and CBT, in patients with anorexia nervosa (food exposure therapy) (Steinglass et al., 2007) and obsessive-compulsive and panic disorder as well as with phobias (Davis, 2011).”
BackgroundInfluentialD-Cycloserine Effects on Extinction of Conditioned Responses to Drug-Related Cues
Myers, K. M., & Carlezon, W. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.030 · Cited by 72
Hillman, B. G., Gupta, S. C., Stairs, D. J., Buonanno, A., & Dravid, S. M. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.01.008 · Cited by 72
Bontempo, A., Panza, K. E., & Bloch, M. H. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07356 · Cited by 69 · cited 10×
“Further promising results have been found, especially for the combination of DCS and CBT, in patients with anorexia nervosa (food exposure therapy) (Steinglass et al., 2007) and obsessive-compulsive and panic disorder as well as with phobias (Davis, 2011).”
BackgroundInfluentialD-cycloserine for Alzheimer's disease
Jones, R., Laake, K., & Øksengård, A. R. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003153 · Cited by 69
Zalta, A. K., Dowd, S., Rosenfield, D., Smits, J. A. J., Otto, M. W., Simon, N. M., Meuret, A. E., Marques, L., Hofmann, S. G., & Pollack, M. H. (2013) · Depression and Anxiety · doi:10.1002/da.22170 · Cited by 68
Glycine modulation of the phencyclidine binding site in mammalian brain
Thomas, J. W., Hood, W. F., Monahan, J. B., Contreras, P. C., & O’Donohue, T. L. (1988) · Brain Research · doi:10.1016/0006-8993(88)91533-8 · Cited by 63
Langton, J. M., & Richardson, R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.32 · Cited by 63 · cited 2×
“Interestingly, facilitation of the fear extinction process works only once, whereas the retrieval of a previous extinction memory (reextinction) seems not to be influenced by DCS (Langton and Richardson, 2008).”
BackgroundChronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence
Popik, P., Wróbel, M., & Nowak, G. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00090-3 · Cited by 62
Effects of REM deprivation and an NMDA agonist on the extinction of conditioned fear
Silvestri, A. J., & Root, D. H. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.08.020 · Cited by 59
STEINGLASS, J., SYSKO, R., SCHEBENDACH, J., BROFT, A., STROBER, M., & WALSH, B. T. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000281484.89075.a8 · Cited by 56 · cited 1×
“Further promising results have been found, especially for the combination of DCS and CBT, in patients with anorexia nervosa (food exposure therapy) (Steinglass et al., 2007) and obsessive-compulsive and panic disorder as well as with phobias (Davis, 2011).”
BackgroundD-cycloserine and cocaine cue reactivity: preliminary findings
Price, K. L., McRae-Clark, A. L., Saladin, M. E., Maria, M. M. M.-S., DeSantis, S. M., Back, S. E., & Brady, K. T. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990903384332 · Cited by 54
Watanabe, Y., Saitō, H., & Abe, K. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)94837-l · Cited by 53
D-Cycloserine Treatment of Alzheimer Disease
Randolph, C., Roberts, J. W., Tierney, M. C., Bravi, D., Mouradian, M. M., & Chase, T. N. (1994) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199408030-00006 · Cited by 52
Evaluation of Cycloserine in the Treatment of Alzheimer's Disease
Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C., Schwartz, P., Hantsburger, G., Herting, R., Swabb, E. A., & Cutler, N. R. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800405 · Cited by 50
Właź, P., Baran, H., & Löscher, W. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90132-5 · Cited by 47
Effects of D-Cycloserine on Extinction: Consequences of Prior Exposure to Imipramine
Werner-Seidler, A., & Richardson, R. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.010 · Cited by 43
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition
D, N. E. M. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200205000-00085 · Cited by 43
d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window
Adeleye, A., Shohami, E., Nachman, D., Alexandrovich, A., Trembovler, V., Yaka, R., Shoshan, Y., Dhawan, J., & Biegon, A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.066 · Cited by 41
Urbano, M., Okwara, L., Manser, P., Hartmann, K., & Deutsch, S. I. (2015) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.13070155 · Cited by 39
Baran, H., Gramer, M., & Löscher, W. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)00745-s · Cited by 36
d-Cycloserine for the treatment of ataxia in spinocerebellar degeneration
Ogawa, M., Shigeto, H., Yamamoto, T., Oya, Y., Wada, K., Nishikawa, T., & Kawai, M. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00009-1 · Cited by 33
Cherry‐Allen, K. M., Lenze, E. J., & Lang, C. E. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00882.2013 · Cited by 32
The stereo-specific effect of d-serine ethylester and the d-cycloserine in ataxic mutant mice
Saigoh, K., Matsui, K., Takahashi, K., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00810-5 · Cited by 22
Spiros, Ä., Roberts, P., & Geerts, H. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00229 · Cited by 18
Nadeau, S. E., Davis, S. E., Wu, S. S., Dai, Y. E., & Richards, L. G. (2014) · Neurorehabilitation and neural repair · doi:10.1177/1545968314532032 · Cited by 15
Chaieb, L., Antal, A., Terney, D., & Paulus, W. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00067 · Cited by 15
Self-citationHistorical Introduction and Chemical Characteristics of Antituberculosis Drugs
Offe, H. A. (1988) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-72873-0_1 · Cited by 11
Who's left? Symptoms of schizophrenia that predict clinical trial dropout
Thompson, J., Berk, M., Dean, O. M., Kohlmann, K., Jeavons, S., Bush, A. I., & Copolov, D. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1253 · Cited by 7
Clinical pharmacology of the antituberculosis drugs
Peloquin, C. A. (2008) · CRC Press eBooks · doi:10.1201/b13468-17 · Cited by 3
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
BackgroundSebih, F., Rousset, M., Bellahouel, S., Rolland, M., de Jesus Ferreira, M. C., Guiramand, J., Cohen-Solal, C., Barbanel, G., Cens, T., Abouazza, M., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00036 · Cited by 24
Donello, J. E., McIntyre, R. S., Pickel, D. B., & Stahl, S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020157 · Cited by 15
“Sarcosine is an orthosteric glycine site-dependent NMDAR agonist, and D-cycloserine is an orthosteric glycine site NMDAR partial agonist [64,65].”
Metadata
- Authors
- Schade, S., & Paulus, W.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Schade, Sebastian
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-12
- Volume
- 19
- Issue
- 4
- Pages
- pyv102
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851259
- OpenAlex
- W2336203720
- Cited by
- 135
- References
- 79
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 10 · 2023: 18 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- D-cycloserine, NMDA receptor partial agonist, schizophrenia, anxiety disorders, addiction, eating disorders, major depressive disorder, autism spectrum disorder, dementia, Alzheimer's disease, spinocerebellar degeneration, dosing and administration, neuropsychiatric disorders
- MeSH terms
- Animals, Mental Disorders, Cycloserine, Humans, Nervous System Diseases, Psychotropic Drugs, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.